This inventor holds 2 USPTO granted patents. Top assignees: University of Washington, Zymogenetics, Inc.. Active years: 1998-2000.
Company Filing History:
2 out of 2,165 
1 out of 723 Years Active: 1998-2000
Title: Catherine E Grubin: Innovator in Diabetes Research
Introduction
Catherine E Grubin is a prominent inventor based in Seattle, WA (US). She has made significant contributions to the field of diabetes research, particularly through her innovative work on human pancreatic islet cell glutamic acid decarboxylase (GAD). With a total of 2 patents, her research has the potential to impact the diagnosis and treatment of insulin-dependent diabetes mellitus (IDDM).
Latest Patents
Catherine's latest patents focus on the cloning and expression of human islet glutamic acid decarboxylase. This autoantigen plays a crucial role in the development of IDDM. Her work involves cloning, sequencing, and expressing GAD through recombinant means. The recombinant human islet cell GAD polypeptides and antibodies specific to these polypeptides can be utilized in various diagnostic and therapeutic methods, including immunoadsorptive therapy and the induction of immune tolerance.
Career Highlights
Throughout her career, Catherine has worked with esteemed institutions such as the University of Washington and Zymogenetics, Inc. Her research has garnered attention for its innovative approach to understanding and treating diabetes.
Collaborations
Catherine has collaborated with notable professionals in her field, including Ake Lernmark and Allan E Karlsen. These collaborations have further enriched her research and contributed to advancements in diabetes treatment.
Conclusion
Catherine E Grubin's work exemplifies the intersection of innovation and medical research. Her contributions to the understanding of diabetes through her patents and collaborations highlight her role as a leading inventor in this critical field.